• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血液透析患者促红细胞生成素剂量的计算机化决策支持

Computerized decision support for EPO dosing in hemodialysis patients.

作者信息

Miskulin Dana C, Weiner Daniel E, Tighiouart Hocine, Ladik Vladimir, Servilla Karen, Zager Philip G, Martin Alice, Johnson H K, Meyer Klemens B

机构信息

Tufts Medical Center, Boston, MA 02111, USA.

出版信息

Am J Kidney Dis. 2009 Dec;54(6):1081-8. doi: 10.1053/j.ajkd.2009.07.010. Epub 2009 Sep 25.

DOI:10.1053/j.ajkd.2009.07.010
PMID:19781831
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2788058/
Abstract

BACKGROUND

Anemia management in hemodialysis patients poses significant challenges. The present study explored the hypothesis that computerized dosing of intravenous erythropoietin (EPO) would increase the percentage of hemoglobin (Hb) values within the target range and reduce staff time spent on anemia management.

STUDY DESIGN

Retrospective cohort.

SETTING & PARTICIPANTS: In-center hemodialysis patients who received EPO at Dialysis Clinic Inc dialysis units for at least 3 months between October 1, 2005, and April 30, 2006.

QUALITY IMPROVEMENT PLAN

Computerized decision support (CDS) for EPO dosing is compared with manual physician-directed dosing.

OUTCOMES

Achieved monthly Hb values, quantity of EPO administered, and time spent by dialysis unit personnel.

MEASUREMENTS

Monthly Hb and quantity of EPO administered to 1,118 patients from 18 dialysis units treated using CDS and 7,823 patients from 125 dialysis units treated using manual dosing.

RESULTS

There was no difference in the likelihood of a monthly Hb level of 11-12 or 10-12 g/dL using CDS compared with manual dosing. The likelihood of an Hb level > 12 g/dL decreased and the likelihood of an Hb level < 10 g/dL increased using CDS. EPO use was 4% lower using CDS, although the difference was not statistically significant. CDS was associated with a nearly 50% decrease (P < 0.001) in the time spent by dialysis unit staff on anemia management.

LIMITATIONS

Retrospective and nonrandomized.

CONCLUSION

The number of monthly Hb values in an 11- (and 10-) to 12-g/dL target range and EPO use did not differ with EPO dosing using CDS compared with manual dosing. Staff resources devoted to anemia management decreased significantly using CDS.

摘要

背景

血液透析患者的贫血管理面临重大挑战。本研究探讨了以下假设:静脉注射促红细胞生成素(EPO)的计算机化给药方案将提高血红蛋白(Hb)值处于目标范围内的百分比,并减少工作人员在贫血管理上花费的时间。

研究设计

回顾性队列研究。

研究地点与参与者

2005年10月1日至2006年4月30日期间,在透析诊所公司透析单元接受EPO治疗至少3个月的中心血液透析患者。

质量改进计划

将EPO给药的计算机化决策支持(CDS)与医生手动指导给药进行比较。

结果

达到的每月Hb值、EPO给药量以及透析单元人员花费的时间。

测量指标

对18个使用CDS治疗的透析单元的1118名患者和125个使用手动给药治疗的透析单元的7823名患者,测量其每月Hb值和EPO给药量。

结果

与手动给药相比,使用CDS时每月Hb水平达到11 - 12或10 - 12 g/dL的可能性没有差异。使用CDS时,Hb水平> 12 g/dL的可能性降低,Hb水平< 10 g/dL的可能性增加。使用CDS时EPO用量降低了4%,尽管差异无统计学意义。CDS与透析单元工作人员在贫血管理上花费的时间减少近50%相关(P < 0.001)。

局限性

回顾性且非随机。

结论

与手动给药相比,使用CDS进行EPO给药时,每月Hb值处于11(和10)至12 g/dL目标范围内的数量以及EPO用量没有差异。使用CDS时,用于贫血管理的人员资源显著减少。

相似文献

1
Computerized decision support for EPO dosing in hemodialysis patients.血液透析患者促红细胞生成素剂量的计算机化决策支持
Am J Kidney Dis. 2009 Dec;54(6):1081-8. doi: 10.1053/j.ajkd.2009.07.010. Epub 2009 Sep 25.
2
2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.2008年日本透析治疗学会:慢性肾脏病肾性贫血指南
Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x.
3
Individualized anemia management in a dialysis facility - long-term utility as a single-center quality improvement experience
.透析机构中的个体化贫血管理——作为单中心质量改进经验的长期效用
Clin Nephrol. 2018 Oct;90(4):276-285. doi: 10.5414/CN109499.
4
Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.慢性肾脏病合并贫血患者接受促红细胞生成素α或达比加群酯治疗时的给药间隔与血红蛋白控制:一项回顾性队列研究
Clin Ther. 2007 Sep;29(9):2010-21. doi: 10.1016/j.clinthera.2007.09.012.
5
Effect of ethnicity on erythropoietin therapy response for hemodialysis patients: a retrospective study.种族对血液透析患者促红细胞生成素治疗反应的影响:一项回顾性研究。
Hemodial Int. 2013 Oct;17(4):510-6. doi: 10.1111/j.1542-4758.2012.00763.x. Epub 2012 Oct 25.
6
Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.静脉注射维生素C对伴有促红细胞生成素低反应性贫血和高铁蛋白血症的血液透析患者的影响。
Am J Kidney Dis. 2006 Apr;47(4):644-54. doi: 10.1053/j.ajkd.2005.12.025.
7
Randomized trial of model predictive control for improved anemia management.随机试验模型预测控制改善贫血管理。
Clin J Am Soc Nephrol. 2010 May;5(5):814-20. doi: 10.2215/CJN.07181009. Epub 2010 Feb 25.
8
Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.2010年至2013年医院血液透析中心(HBDC)的贫血管理趋势
Clin Ther. 2014 Mar 1;36(3):408-18. doi: 10.1016/j.clinthera.2014.01.015. Epub 2014 Feb 28.
9
Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa.慢性肾脏病贫血患者从达比加群酯转换为促红细胞生成素α的给药模式、药物成本和血液学结果。
Curr Med Res Opin. 2007 Aug;23(8):1931-7. doi: 10.1185/030079907X210705.
10
Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).铁储备充足的血液透析患者从皮下给药转换为静脉给药时不需要更高剂量的促红细胞生成素:意大利促红细胞生成素转换研究(ISEC)的结果。
Am J Kidney Dis. 2006 Jun;47(6):1027-35. doi: 10.1053/j.ajkd.2006.02.176.

引用本文的文献

1
Effects of Individualized Anemia Therapy on Hemoglobin Stability: A Randomized Controlled Pilot Trial in Patients on Hemodialysis.个体化贫血治疗对血红蛋白稳定性的影响:一项针对血液透析患者的随机对照试验
Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1138-1147. doi: 10.2215/CJN.0000000000000488. Epub 2024 Jun 11.
2
Physician Compliance With a Computerized Clinical Decision Support System for Anemia Management of Patients With End-stage Kidney Disease on Hemodialysis: Retrospective Electronic Health Record Observational Study.医生对用于血液透析终末期肾病患者贫血管理的计算机化临床决策支持系统的依从性:回顾性电子健康记录观察性研究。
JMIR Form Res. 2023 May 3;7:e44373. doi: 10.2196/44373.
3

本文引用的文献

1
Model predictive control of erythropoietin administration in the anemia of ESRD.终末期肾病贫血中促红细胞生成素给药的模型预测控制
Am J Kidney Dis. 2008 Jan;51(1):71-9. doi: 10.1053/j.ajkd.2007.10.003.
2
The relationship between dialysis performance measures: adequacy and anemia management.
Am J Kidney Dis. 2007 Nov;50(5):774-81. doi: 10.1053/j.ajkd.2007.08.006.
3
Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations.血红蛋白水平变异性:与合并症、并发事件及住院治疗的关联
Multi-head self-attention mechanism enabled individualized hemoglobin prediction and treatment recommendation systems in anemia management for hemodialysis patients.
多头自注意力机制助力于为血液透析患者的贫血管理建立个性化血红蛋白预测及治疗推荐系统。
Heliyon. 2023 Feb 1;9(2):e12613. doi: 10.1016/j.heliyon.2022.e12613. eCollection 2023 Feb.
4
Investigating the Perceptions of Primary Care Dietitians on the Potential for Information Technology in the Workplace: Qualitative Study.调查初级保健营养师对工作场所信息技术潜力的看法:定性研究
J Med Internet Res. 2018 Oct 15;20(10):e265. doi: 10.2196/jmir.9568.
5
Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients.在一大群血液透析患者中,达贝泊汀和铁剂治疗长期血红蛋白反应预测模型的性能。
PLoS One. 2016 Mar 3;11(3):e0148938. doi: 10.1371/journal.pone.0148938. eCollection 2016.
6
Successful creation of an anemia management algorithm for hemodialysis patients.成功创建血液透析患者贫血管理算法。
Int J Nephrol Renovasc Dis. 2015 Jun 23;8:65-75. doi: 10.2147/IJNRD.S80723. eCollection 2015.
7
Dashboard systems: implementing pharmacometrics from bench to bedside.仪表盘系统:将药物计量学从实验室应用到临床
AAPS J. 2014 Sep;16(5):925-37. doi: 10.1208/s12248-014-9632-5. Epub 2014 Jun 20.
8
Trends in anemia management in US hemodialysis patients 2004-2010.美国血液透析患者 2004-2010 年贫血管理趋势。
BMC Nephrol. 2013 Dec 1;14:264. doi: 10.1186/1471-2369-14-264.
9
Comparative effectiveness studies to improve clinical outcomes in end stage renal disease: the DEcIDE patient outcomes in end stage renal disease study.比较效果研究以改善终末期肾病的临床结局:DEcIDE 终末期肾病患者结局研究。
BMC Nephrol. 2012 Dec 6;13:167. doi: 10.1186/1471-2369-13-167.
10
Benefits and drawbacks of electronic health record systems.电子健康记录系统的优缺点。
Risk Manag Healthc Policy. 2011;4:47-55. doi: 10.2147/RMHP.S12985. Epub 2011 May 11.
Clin J Am Soc Nephrol. 2006 Nov;1(6):1205-10. doi: 10.2215/CJN.01110306. Epub 2006 Sep 6.
4
Functional data analysis applied to a randomized controlled clinical trial in hemodialysis patients describes the variability of patient responses in the control of renal anemia.应用于血液透析患者随机对照临床试验的功能数据分析描述了肾性贫血控制中患者反应的变异性。
J Am Soc Nephrol. 2007 Aug;18(8):2371-6. doi: 10.1681/ASN.2006050436. Epub 2007 Jul 11.
5
Development and exploitation of a clinical decision support system for the management of renal anaemia.用于肾性贫血管理的临床决策支持系统的开发与应用
Nephrol Dial Transplant. 2007 Jun;22 Suppl 4:iv31-iv36. doi: 10.1093/ndt/gfm163.
6
Medication-related clinical decision support in computerized provider order entry systems: a review.计算机化医嘱录入系统中与药物治疗相关的临床决策支持:综述
J Am Med Inform Assoc. 2007 Jan-Feb;14(1):29-40. doi: 10.1197/jamia.M2170. Epub 2006 Oct 26.
7
KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.《慢性肾脏病贫血的改善全球肾脏病预后组织临床实践指南及临床实践建议》
Am J Kidney Dis. 2006 May;47(5 Suppl 3):S11-145. doi: 10.1053/j.ajkd.2006.03.010.
8
Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success.使用临床决策支持系统改善临床实践:对确定成功关键特征的试验进行系统评价。
BMJ. 2005 Apr 2;330(7494):765. doi: 10.1136/bmj.38398.500764.8F. Epub 2005 Mar 14.
9
Dosage individualization of erythropoietin using a profile-dependent support vector regression.
IEEE Trans Biomed Eng. 2003 Oct;50(10):1136-42. doi: 10.1109/TBME.2003.816084.
10
Protocolized anemia management with erythropoietin in hemodialysis patients: a randomized controlled trial.
J Am Soc Nephrol. 2003 Oct;14(10):2654-61. doi: 10.1097/01.asn.0000088026.88074.20.